This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Reports Third Quarter 2011 Financial Results

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the third quarter ended September 30, 2011.

"The third quarter marked an important period for Curis, due to our collaborator Genentech's NDA submission to the FDA seeking sales and marketing approval for vismodegib (GDC-0449, RG3616) in the U.S. to treat people with advanced basal cell carcinoma (BCC),” said Dan Passeri, Curis President and Chief Executive Officer. “We believe that this first-in-class molecule has the potential to provide an important new treatment option for patients with advanced BCC. Importantly, Curis is eligible to receive an $8 million milestone payment from Genentech upon FDA acceptance of this submission and, if the drug subsequently receives FDA approval, we will receive an additional milestone payment as well as royalties on any future sales. We also continue to anticipate that Roche will file an MAA submission with the EMA for regulatory approval of vismodegib in the European Union, the timing of which is subject to ongoing discussions between Roche and European health authorities.”

Mr. Passeri continued, "In addition, we continued to advance our pipeline, beginning with our Phase I dose escalation, combination trial of our first-in-class EGFR, Her2 and HDAC inhibitor CUDC-101 in head and neck cancer patients. We also completed enrollment in our Phase I expansion study of CUDC-101 in several cancer types and are very pleased with the results observed to-date, which include observations of long-term stable disease across several cancer types, data that demonstrate that we are hitting our intended molecular targets and a favorable safety profile, consistent with that observed in our Phase I dose escalation study. Looking ahead, we expect to initiate a Phase I clinical trial for an oral formulation of CUDC-101 and also a Phase I trial for new development candidate CUDC-907, a PI3K and HDAC inhibitor, in the first half of 2012, and Debiopharm, our licensee for our Hsp90 inhibitor Debio 0932, has indicated that it plans to initiate Phase Ib studies of Debio 0932 in the near term.”

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.27 0.00%
FB $101.00 0.00%
GOOG $684.12 0.00%
TSLA $143.67 0.00%
YHOO $27.10 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs